Company news
Recce Pharmaceuticals Ltd. (ASX:RCE) news
Recce Pharmaceuticals Ltd. news releases on 6ix. Latest, Oct 31, 2017: Appendix 4C - quarterly
Press releases — page 5
Appendix 4C - quarterly
October 31, 2017
Recce Launches Share Purchase Plan
September 27, 2017
Response to ASX Price Query
September 18, 2017
Recce Confirms Pre-IND Data Submission to US FDA
September 6, 2017
Appendix 4E and Financial Report
August 31, 2017
Recce Confirms Delivery by Intravenous Drip
July 30, 2017
Recce achieves milestone with volume production
July 19, 2017
Recce constructs automated manufacturing facility to support
June 22, 2017
Recce secures up to A$6.05 million investment agreement with
June 16, 2017
Recce moves closer to clinical study application
May 19, 2017
Operational Update
April 9, 2017
Data from large animal study shows RECCE 327 well tolerated
March 26, 2017
Appendix 4D and Interim Financial Statements
February 28, 2017
Microscopy Images of its Synthetic Antibiotic in Action Dest
February 23, 2017
Recce to suspend anti-cancer program
February 22, 2017
Operational Update and Quarterly Cash Flow
January 30, 2017
Lead compound reduces illness in mice infected by E.coli
January 17, 2017
Encouraging anti-viral activity for lead compound RECCE 327
December 20, 2016
Pre-clinical toxicology and efficacy testing
November 2, 2016
Dose Ranging in Mice - Repeated Success
August 15, 2016
Successful Test Results for Genetic Toxicity
July 20, 2016
Anti-viral Activity
July 13, 2016
Update on Testing Schedules
June 20, 2016
Encouraging Results from Safety Test
May 25, 2016
Recce - The Way Forward
May 2, 2016
Progress Update
April 10, 2016
International Trade Mark Registrations
April 5, 2016
Anti-cancer Activities
March 13, 2016
Appendix 4D and Half Year Financial Statements
February 26, 2016
Efficacy without Toxicity
February 11, 2016
RECCE Antibiotic kills TB and Gonorrhoea
February 10, 2016